

**AML 17 - APL treatment**  
**Induction**  
**Tretinoin (ATRA) with Arsenic Trioxide**

<b>Height</b>	cm
<b>Weight</b>	kg
<b>BSA</b>	m <sup>2</sup>

--

Destination	BMTU

		<b>Limits</b>
Date		
Neuts		
Plats		

**Hypersensitivities/Allergies**

**Antiemetics**  
 Domperidone 10mg PO QID  
 +/- Cyclizine 50 mg PO / IV TDS

	<b>Agent</b>	<b>Round</b>
	Tretinoin (ATRA)	10 mg
	Arsenic Trioxide	1 mg

**DOSE MODIFIED: No Yes**

Reference: AML 17 trial protocol

Day	Date	Time	Agent	Dose	Route	Instructions	Doctor	Nurse	Check	Start	Stop
1			Tretinoin (ATRA) 45mg/m <sup>2</sup>	mg	PO	Administered daily in 2 equally divided doses, from day 1 until Haematological CR or for a maximum of 60 days. Chart on regular medication chart or outpatient prescription.					
			Arsenic trioxide 0.3mg/kg	mg	IV						
2			Arsenic trioxide 0.3mg/kg	mg	IV	In 250 mL sodium chloride 0.9 % over 2 hours					
3			Arsenic trioxide 0.3mg/kg	mg	IV	In 250 mL sodium chloride 0.9 % over 2 hours					
4			Arsenic trioxide 0.3mg/kg	mg	IV	In 250 mL sodium chloride 0.9 % over 2 hours					
5			Arsenic trioxide 0.3mg/kg	mg	IV	In 250 mL sodium chloride 0.9 % over 2 hours					

- You must read the protocol before prescribing this chemotherapy.
- Baseline ECG + weekly. Ensure Mg > 0.7 mmol/L and K<sup>+</sup> > 4 mmol/L prior to each dose of arsenic trioxide
- \* Monitor closely for signs of differentiation (ATRA) syndrome and tumour lysis syndrome. See Red book for details.

**Consultant:**  
**NZMC Reg. No:**